Bluejay Diagnostics Reports Q1 2026 Financial Results with Increased Net Loss

Bluejay Diagnostics, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of approximately $1.9 million, a slight increase from a net loss of $1.86 million in the same period of 2025. The company's total operating expenses rose to $1.94 million, compared to $1.89 million in the prior year, primarily driven by increased research and development costs. The company’s cash and cash equivalents decreased to $3.68 million as of March 31, 2026, down from $5.16 million at the end of 2025, reflecting ongoing operational expenditures.

In terms of operational metrics, Bluejay's research and development expenses were approximately $811,837 for the first quarter of 2026, compared to $784,800 in the same quarter of 2025. General and administrative expenses remained relatively stable at around $1.13 million for both periods. The company’s accumulated deficit increased to $43.44 million as of March 31, 2026, highlighting the ongoing financial challenges it faces as it develops its Symphony technology platform, which aims to provide rapid diagnostic testing for critical care settings.

Strategically, Bluejay has made significant progress in its Symphony platform, which includes the Symphony IL-6 test aimed at monitoring disease progression in sepsis patients. The company has transitioned the manufacturing of its cartridges to Sanyoseiko, a contract manufacturing organization, and is working towards regulatory submission to the FDA. The company anticipates needing to raise at least $20 million by the end of the 2027 fiscal year to support its operations and clinical trials, with plans to begin testing samples collected as part of its SYMON-II clinical trial by the end of 2026.

The company’s operational developments also include a recent private placement in March 2026, where it raised $125,000 by issuing 62,500 shares of common stock. This funding is part of Bluejay's efforts to secure additional capital to support its ongoing projects. However, the company has expressed concerns regarding its ability to continue as a going concern, given its negative cash flow and the need for substantial future financing. The current cash resources are expected to fund operations only through the third quarter of 2026, underscoring the urgency for additional capital to sustain its business and regulatory efforts.